The COVID-19 treatment remdesivir dominated hospital drug spending in 2021, accounting for nearly 10% of all pharmaceutical expenses and outpacing the next three drugs combined, according to the National Trends in Prescription Drug Expenditures and Projections for 2022.
Report: Remdesivir dominated hospital drug spending in 2021
The COVID-19 treatment remdesivir dominated hospital drug spending in 2021, accounting for nearly 10% of all pharmaceutical expenses and outpacing the next three drugs combined, according to the National Trends in Prescription Drug Expenditures and Projections for 2022.